Efficacy and Toxicity of Doxorubicin/Cyclophosphamide Maintenance Therapy in Dogs with Multicentric Lymphosarcoma

Price, G. Sylvester; Page, Rodney L.; Fischer, Britta; Levine, Jay F.; Gerig, Thomas M.

doi:10.1111/j.1939-1676.1991.tb03131.x

Cited by 92 publications

(65 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Much attention is paid to a worse response to treatment in patients treated with steroids prior to the relevant chemotherapy. This phenomenon is not fully understood (17). An activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive, poorly chemoresponsive lymphoid malignancy.…”

Section: Discussionmentioning

confidence: 99%

In vitro drug sensitivity in canine lymphoma

Pawlak¹,

Obmińska-Mrukowicz²,

Zbyryt³

et al. 2016

Journal of Veterinary Research

View full text Add to dashboard Cite

Introduction: Due to the high heterogeneity of canine lymphoma, the aim of the present study was to test in vitro the chemosensitivity of canine high-grade primary lymphoma cells to various cytostatic drugs commonly used to treat dogs: 4-HO-cyclophosphamide, doxorubicin, dexamethasone, prednisolone, vincristine, etoposide, chlorambucil, lomustine, and cytosine arabinoside. Material and Methods: To determine the cell viability and drug ability to induce apoptosis two different tests were used: an MTT assay and annexin V/propidium iodide staining. Results: Both in vitro tests were found to be useful tools. Significant differences in the sensitivity, depending on the drug type, between B-, T-and mixed/null-type lymphoma cells were found for the majority of the tested drugs. B-type cells were the most sensitive in vitro, whereas T-type cells seemed to be the most resistant. Doxorubicin, chlorambucil, etoposide, and vincristine most strongly reduced the cell viability and induced apoptosis. Conclusion: In vitro assays, such as the MTT test and especially the annexin V/PI assay, may be useful tools for predicting a response to the treatment of high-grade lymphoma in dogs or improving the treatment outcomes in individual animals.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro drug sensitivity in canine lymphoma

Pawlak¹,

Obmińska-Mrukowicz²,

Zbyryt³

et al. 2016

Journal of Veterinary Research

View full text Add to dashboard Cite

show abstract

“…1st remissions last 4-14 months. [6][7][8][9][10][11][12][13][14] Rescue therapy attempts to establish remission in an animal with lymphoma that has failed 1st-line treatments or to reestablish remission in an animal that has relapsed after previous treatment. Unfortunately, durable remissions with rescue therapy are uncommon in dogs.…”

mentioning

confidence: 99%

MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989–2000)

Rassnick

Mauldin

Al-Sarraf

et al. 2002

Veterinary Internal Medicne

View full text Add to dashboard Cite

The purpose of this retrospective study was to evaluate the efficacy and toxicity of the MOPP chemotherapy protocol (mechlorethamine, vincristine, procarbazine, and prednisone) as a rescue regimen in dogs with lymphoma. One hundred seventeen dogs that had resistance to previously administered chemotherapy were evaluated. Before treatment with MOPP, all dogs received a median of 6 chemotherapy drugs for a median duration of 213 days. Thirty-one percent (36 of 117) had a complete response (CR) to MOPP for a median of 63 days, and 34% (40 of 117) had a partial response (PR) for a median of 47 days. Sixteen percent (19 of 117) had stable disease (SD) for a median of 33 days. Predictors for response to MOPP were not identified. Gastrointestinal (GI) toxicity occurred in 28% (33 of 117) of the dogs, and 13% (15 dogs) required hospitalization. Five dogs developed septicemia, and 2 died as a result. MOPP was an effective treatment for dogs with resistant lymphoma and was well tolerated by the majority of affected dogs.Key words: Canine; Lymphosarcoma; Rescue. The MOPP chemotherapy protocol (mechlorethamine, a vincristine, b procarbazine, c and prednisone) was designed by DeVita et al in 1964 and was the 1st successful combined drug regimen for the treatment of humans with Hodgkin's and non-Hodgkin's lymphoma.1,2 Up to 85% of humans with advanced lymphoma and no previous chemotherapy exposure will achieve a complete remission when treated with MOPP. Approximately 70% of these remissions are durable, and disease-free long-term survivors have a high chance of being cured.2,3 Currently, several alternative chemotherapeutic regimens with superior results and often fewer toxicities exist for use in humans. 4,5 However, the development of MOPP was a milestone in oncology, demonstrating that advanced disease could be controlled.Durable 1st remissions are achievable in Ͼ80% of previously untreated dogs with lymphoma by combination chemotherapy protocols. 1st remissions last 4-14 months. [6][7][8][9][10][11][12][13][14] Rescue therapy attempts to establish remission in an animal with lymphoma that has failed 1st-line treatments or to reestablish remission in an animal that has relapsed after previous treatment. Unfortunately, durable remissions with rescue therapy are uncommon in dogs. Most rescue protocols Veterinary Medicine, Cornell University, Ithaca, NY 14853; e-mail: kmr32@cornell.edu. Submitted December 10, 2001; Revised February 19, 2002; Accepted March 19, 2002. Copyright ᭧ 2002 result in 30-50% response rates. 2nd remission durations using rescue protocols are also relatively short, generally 1-5 months. 15-18Although high response rates and prolonged remission durations are documented in humans with lymphoma treated with the MOPP chemotherapy, few reports describe the use of the MOPP protocol in dogs with lymphoma (Rosenberg and Matus, personal communication). The objectives of this retrospective study were to evaluate the toxicity and relative efficacy of the MOPP protocol when used as a rescue therapy in dogs wi...

show abstract

“…Until now, however, prognostic factors have not yet been used in the formulation and modification of treatment protocols in animals as they have been used in humans. Sex (4,6), age (7), body weight (16) (16), and prior treatment with prednisolone (12) have been reported to be valuable indicators for predicting relapse, survival, or both. In the present study, an elevated pretreatment plasma creatinine concentration and leucocytosis were associated with a decreased duration of the disease-free period.…”

mentioning

confidence: 99%

“…Pretreatment with prednisolone has also been reported to decrease the duration of remission (12). This implies that veterinary practitioners should refrain from administering glucocorticoids to dogs with malignant lymphoma before chemotherapy is started by a veterinary oncologist.…”

mentioning

confidence: 99%

Evaluation of the results of a L‐asparaginase‐based continuous chemotherapy protocol versus a short doxorubicin‐based induction chemotherapy protocol in dogs with malignant lymphoma

Piek

Rutteman²,

Teske³

1999

Veterinary Quarterly

View full text Add to dashboard Cite

SUMMARYThe results of an L-asparaginase-based continuous chemotherapy protocol (n = 52) versus a short doxorubicin-based induction chemotherapy protocol (n = 65) were evaluated in 117 dogs with malignant lymphoma. There were no differences between the two groups in patient characteristics or incidence of protocol-related toxicity. Complete remission was induced in 71.2% of the dogs treated with the Lasparaginase protocol and in 67.7% of the dogs treated with the doxorubicin-plus protocol. The calculated Kaplan-Meier one-and two-year survival fractions in the L-asparaginase group were 48% and 26%, and in the doxorubicin-plus group 35%, and 22%, respectively. Differences in remission and survival between the two treatment groups were not significant. A multivariate Cox proportional hazards survival analysis revealed that elevated pretreatment plasma creatinine concentration and prior treatment with prednisolone were associated with shorter survival times. An elevated pretreatment plasma creatinine concentration and total leucocyte count were associated with a decrease in the disease-free period. Differences in efficacy and toxicity between the two protocols were not significant. There is no apparent advantage in using the continuous L-asparaginase protocol, and the shorter doxorubicin-plus protocol is less expensive and less time consuming.

show abstract

Efficacy and Toxicity of Doxorubicin/Cyclophosphamide Maintenance Therapy in Dogs with Multicentric Lymphosarcoma

Cited by 92 publications

References 1 publication

In vitro drug sensitivity in canine lymphoma

In vitro drug sensitivity in canine lymphoma

MOPP Chemotherapy for Treatment of Resistant Lymphoma in Dogs: A Retrospective Study of 117 Cases (1989–2000)

Evaluation of the results of a L‐asparaginase‐based continuous chemotherapy protocol versus a short doxorubicin‐based induction chemotherapy protocol in dogs with malignant lymphoma

Contact Info

Product

Resources

About